Tissue-Based Diagnostic Biomarkers of Aggressive Variant Prostate Cancer: A Narrative Review
- PMID: 38398199
- PMCID: PMC10887410
- DOI: 10.3390/cancers16040805
Tissue-Based Diagnostic Biomarkers of Aggressive Variant Prostate Cancer: A Narrative Review
Abstract
Prostate cancer (PC) is a common malignancy among elderly men, characterized by great heterogeneity in its clinical course, ranging from an indolent to a highly aggressive disease. The aggressive variant of prostate cancer (AVPC) clinically shows an atypical pattern of disease progression, similar to that of small cell PC (SCPC), and also shares the chemo-responsiveness of SCPC. The term AVPC does not describe a specific histologic subtype of PC but rather the group of tumors that, irrespective of morphology, show an aggressive clinical course, dictated by androgen receptor (AR) indifference. AR indifference represents an adaptive response to androgen deprivation therapy (ADT), driven by epithelial plasticity, an inherent ability of tumor cells to adapt to their environment by changing their phenotypic characteristics in a bi-directional way. The molecular profile of AVPC entails combined alterations in the tumor suppressor genes retinoblastoma protein 1 (RB1), tumor protein 53 (TP53), and phosphatase and tensin homolog (PTEN). The understanding of the biologic heterogeneity of castration-resistant PC (CRPC) and the need to identify the subset of patients that would potentially benefit from specific therapies necessitate the development of prognostic and predictive biomarkers. This review aims to discuss the possible pathophysiologic mechanisms of AVPC development and the potential use of emerging tissue-based biomarkers in clinical practice.
Keywords: ADT; AVPC; DDR; NEPC; biomarkers; epigenetic regulation; transdifferentiation; tumor suppressors.
Conflict of interest statement
The authors declare no conflicts of interest.
Figures
![Figure 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/10887410/bin/cancers-16-00805-g001.gif)
![Figure 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/10887410/bin/cancers-16-00805-g002.gif)
Similar articles
-
Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate Cancers.Clin Cancer Res. 2016 Mar 15;22(6):1520-30. doi: 10.1158/1078-0432.CCR-15-1259. Epub 2015 Nov 6. Clin Cancer Res. 2016. PMID: 26546618 Free PMC article.
-
Neuroendocrine and Aggressive-Variant Prostate Cancer.Cancers (Basel). 2020 Dec 16;12(12):3792. doi: 10.3390/cancers12123792. Cancers (Basel). 2020. PMID: 33339136 Free PMC article. Review.
-
Epigenetic reprogramming: A key mechanism driving therapeutic resistance.Urol Oncol. 2018 Aug;36(8):375-379. doi: 10.1016/j.urolonc.2017.12.021. Epub 2018 Feb 1. Urol Oncol. 2018. PMID: 29395951 Review.
-
Androgen Receptor Signaling in Castration-Resistant Prostate Cancer Alters Hyperpolarized Pyruvate to Lactate Conversion and Lactate Levels In Vivo.Mol Imaging Biol. 2019 Feb;21(1):86-94. doi: 10.1007/s11307-018-1199-6. Mol Imaging Biol. 2019. PMID: 29748904 Free PMC article.
-
Genotype-to-Phenotype Associations in the Aggressive Variant Prostate Cancer Molecular Profile (AVPC-m) Components.Cancers (Basel). 2022 Jun 30;14(13):3233. doi: 10.3390/cancers14133233. Cancers (Basel). 2022. PMID: 35805010 Free PMC article.
References
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous